Table 1 Baseline demographics and clinical characteristics
|  | Placebo (n = 201) | Mepolizumab 100 mg SC (n = 206) | Total (n = 407) |
|---|---|---|---|
Age, years, mean (SD) | 48.9 (12.5) | 48.6 (13.6) | 48.8 (13.0) |
Male, n (%) | 125 (62) | 139 (67) | 264 (65) |
Blood eosinophil count, cells/µL, geometric mean (standard logs) | 400 (0.775) | 390 (0.755) | – |
Patients with asthma, n (%) | 149 (74) | 140 (68) | 289 (71) |
Patients with N-ERD, n (%) | 63 (31) | 45 (22) | 108 (27) |
Nasal surgeries in previous 10Â years | |||
 1 | 81 (40) | 108 (52) | 189 (46) |
 2 | 47 (23) | 47 (23) | 94 (23) |
 > 2 | 73 (36) | 51 (25) | 124 (30) |
Duration of NP, years, mean (SD) | 11.46 (8.27) | 11.36 (8.52) | 11.41 (8.39) |
VAS score*, median (range) | |||
 Nasal obstruction | 9.1 (5.3–10.0) | 9.0 (6.5–10.0) | 9.1 (5.3–10.0) |
 Loss of sense of smell | 10.0 (6.7–10.0) | 10.0 (0.9–10.0) | 10.0 (0.9–10.0) |
 Overall symptoms | 9.2 (7.2–10.0) | 9.1 (7.2–10.0) | 9.2 (7.2–10.0) |
 Nasal discharge | 9.0 (1.4–10.0) | 8.9 (1.0–10.0) | – |
 Mucus in throat | 9.1 (0.5–10.0) | 8.9 (0.2–10.0) | – |
 Facial pain | 8.9 (0.0–10.0) | 8.5 (0.0–10.0) | – |
SNOT-22 total score, median (range)* | 64.0 (19–110) | 64.0 (17–105) | 64.0 (17–110) |
Total endoscopic score, median (range) (scale: 0–8) | 6.0 (0–8) | 5.0 (2–8) | – |
PNIF, median (range) | 90.0 (0–380) | 92.5 (0–350) | – |
ACQ-5 score, mean (SD)†| 2.2 (1.4) | 2.4 (1.4) | – |